Search

Your search keyword '"Antonella d'Arminio Monforte"' showing total 10 results
Start Over Author "Antonella d'Arminio Monforte" Database Complementary Index
10 results on '"Antonella d'Arminio Monforte"'

2. Highly Active Antiretroviral Therapy Reduces the Age-Associated Risk of Dementia in a Cohort of Older HIV-1-Infected Patients.

Author

Dora Larussa, Patrizia Lorenzini, Antonella Cingolani, Simona Bossolasco, Susanna Grisetti, Marco Bongiovanni, Francesca Moretti, Ilaria Uccella, Paolo Zannoni, Sergio Foresti, Giovanni Mazzarello, Maria Irene Arcidiacono, Rosa Pedale, Adriana Ammassari, Valerio Tozzi, Carlo Federico Perno, Antonella D'Arminio Monforte, Paola Cinque, and Andrea Antinori

Published
2006

5. Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.

Author

Marco Bongiovanni, Elisabetta Chiesa, Antonio Di Biagio, Paola Meraviglia, Amedeo Capetti, Federica Tordato, Paola Cicconi, Patrizia Biasi, Teresa Bini, and Antonella d'Arminio Monforte

Abstract

Objectives: The long-term virological efficacy of lopinavir/ritonavir-containing highly active antiretroviral therapy (HAART) in HIV-infected patients failing a first-line protease inhibitor (PI)-based regimen is still unclear.Methods: An observational study was carried out from December 2000–December 2002 on 111 consecutive patients starting lopinavir/ritonavir. The primary end-point was virological success (HIV RNA <50 copies/mL in two consecutive determinations). CD4 outcome, lipid levels and adverse events were recorded. The Kaplan–Meier method and log-rank test were used to estimate the time-dependent probability of reaching the end-point using intention-to-treat and on-treatment approaches.Results: Ninety-six patients obtained virological success during follow-up; Kaplan–Meier analysis showed that the time-dependent probability of obtaining this end-point was 78.4% at month 12 and 85.8% at month 24. The median CD4+cell count increased by 118 cells/mm3 from baseline to month 12 and by 153 cells/mm3 to month 24. Thirty-one patients discontinued lopinavir/ritonavir: 16 because of drug-related toxicities, six for simplification, five because of virological failure, one patient was lost at follow-up and three died. An elevation in lipid parameters was observed, but only a minority of patients developed a grade 3 or higher hypertriglyceridaemia and/or hypercholesterolaemia. Among the 15 patients not reaching virological success, five had ≤5 mutations in the protease region known to reduce susceptibility to lopinavir/ritonavir (one discontinued lopinavir/ritonavir because of gastrointestinal intolerance), five had no mutations (two discontinued lopinavir/ritonavir because of gastrointestinal intolerance) and five showed ≥6 mutations (all discontinued lopinavir/ritonavir); however, of the patients who discontinued lopinavir/ritonavir none achieved HIV RNA <50 copies/mL on subsequent regimens.Conclusions: Lopinavir/ritonavir was highly effective and well tolerated in HIV-infected patients failing a first-line PI-based HAART. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

7. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome–related Kaposi sarcoma(Performed on behalf of the Gruppo Italiano Cooperativo AIDS & Tumori (GICAT) and the Italian Cohort of Naive Antiretroviral Patients (ICONA) study groups.)The following are members of the GICAT: Daniele Bernardi, Massimiliano Berretta, Roberta Cinelli, Giampiero di Gennaro, Mariagrazia Michieli, Isabella Milan, Maurizio Rupolo, Ornella Schioppa, Cecilia Simonelli, Michele Spina, Giuseppe Vultaggio, and Martina Zanetti (Aviano, Italy); Pierluigi Blanc (Bagno Ripoli, Italy); Giampiero Carosi and Massimo Puoti (Brescia, Italy); Giuliano Rizzardini and Claudia Zeroli (Busto Arsizio, Italy); Benedetto M. Celesia and Luciano Nigro (Catania, Italy); Ampelio Tocchetti (Como, Italy); Angelo Pan (Cremona, Italy); Francesco Mazzotta (Florence, Italy); Sante Grisorio (Foggia, Italy); Paolo Tundo (Galatina, Italy); Adriana Albini (Genoa, Italy); Marco Fasan, Giuseppe Landonio, Adriano Lazzarin, Carla Pastecchia, and Annalisa Ridolfo (Milan, Italy); Alberto Dolara (Monza, Italy); Vincenzo Montesarchio (Naples, Italy); Pietro L. Garavelli (Novara, Italy); Francesco Di Lorenzo and Salvatrice Mancuso (Palermo, Italy); Guido Chichino and Renato Maserati (Pavia, Italy); Daniela Padrini (Piacenza, Italy); Beatrice Adriani (Prato, Italy); Carla Lovigu (Sassari, Italy); Saverio Di Lorenzo (Sondalo, Italy); Ivano Dal Conte, Ezio Nigra, Filippo Lipani, and Alessandro Sinicco (Turin, Italy); Palma Delle Foglie (Trento, Italy); Alberto Vaglia (Treviso, Italy); Pierluigi Viale (Udine, Italy); and Enzo Raise (Venice, Italy).)

Author

Guglielmo Nasti, Ferdinando Martellotta, Massimiliano Berretta, Maurizio Mena, Marco Fasan, Giovanni Di Perri, Renato Talamini, Gabriella Pagano, Maria Montroni, Roberta Cinelli, Emanuela Vaccher, Antonella D'Arminio Monforte, and Umberto Tirelli

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results